NCT04750824View on ClinicalTrials.gov

Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.

CompletedOBSERVATIONAL
Enrollment

110

Participants

Timeline

Start Date

October 15, 2020

Primary Completion Date

December 20, 2021

Study Completion Date

December 20, 2021

Conditions
Non-squamous, Non-Small Cell Lung Cancer
Interventions
DRUG

Afatinib

Afatinib

DRUG

other systemic therapy

other systemic therapy

Trial Locations (1)

43017

Cardinal Health, Dublin

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04750824 - Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S. | Biotech Hunter | Biotech Hunter